LATEST NEWS
General, Central Obesity Linked to Specific Breast Cancer Risk
 

(HealthDay News) General and central obesity are associated with breast cancer risk, with different effects on specific subtypes, research in The Oncologist suggests. Researchers conducted a case-contro...
Wed, 20 Sep 2017 HEMATOLOGY & ONCOLOGY

Extended Thromboprophylaxis Safe, Effective After Liver Surgery
 

(HealthDay News) For patients undergoing liver surgery, extended pharmacologic thromboprophylaxis appears effective and safe, research in the Journal of Thrombosis and Haemostasis suggests. A total of 1...
Tue, 19 Sep 2017 HEMATOLOGY & ONCOLOGY

Skin Cancer Prevention Strategies Needed in Work Settings
 

(HealthDay News) Solar occupational ultraviolet (UV) exposure is a major determinant of incident squamous cell carcinoma (SCC), according to research in the British Journal of Dermatology. Non-occupatio...
Mon, 18 Sep 2017 HEMATOLOGY & ONCOLOGY

Good Survival for HSCT-Treated Thalassemia Patients
 

(HealthDay News) Patients with thalassemia treated with hematopoietic stem cell transplantation (HSCT) have 30-year survival that's similar to that of conventionally treated (CT) patients, research in t...
Thu, 14 Sep 2017 HEMATOLOGY & ONCOLOGY

Most Opioid Use Concentrated in Top 10 Percent of Users
 

(HealthDay News) The top 10% of privately insured U.S. adults without cancer using opioids account for most opioid use, according to a research letter published in the Annals of Internal Medicine. The r...
Tue, 12 Sep 2017 HEMATOLOGY & ONCOLOGY

Diverse Neurological Effects Linked to Anti-PD-1 Therapy
 

(HealthDay News) Neurological complications associated with anti-programmed death 1 (PD-1) antibody treatment have a diverse phenotype, according to research in JAMA Neurology. “Neurological adver...
Mon, 11 Sep 2017 HEMATOLOGY & ONCOLOGY

Immunosuppressant Response Predicts Aplastic Anemia Survival
 

(HealthDay News) Response to immunosuppressive therapy (IST) predicts overall survival (OS) in aplastic anemia (AA), research in the American Journal of Hematology finds. Researchers found that OS was s...
Thu, 07 Sep 2017 HEMATOLOGY & ONCOLOGY

No Difference in Toxicity for 6-, 2-Fraction HDR in Prostate Cancer
 

(HealthDay News) For men with prostate cancer there's no difference in acute genitourinary or sexual dysfunction between 6- and 2-fraction high-dose-rate (HDR) brachytherapy monotherapy, research in the...
Thu, 07 Sep 2017 HEMATOLOGY & ONCOLOGY